Compare IDEXX Laboratories, Inc. (IDXX) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JD.Com Inc — how do they compare? IDEXX Laboratories, Inc. trades at $521.8 (market cap $40.60B), while JD.Com Inc trades at $27.34 (market cap $36.70B). The key difference: IDEXX Laboratories, Inc. and JD.Com Inc are close in size by market cap, and JD.Com Inc pays a 3.67% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and JD.Com Inc for 85 Days on average.
| IDXX | JD | |
|---|---|---|
Market Cap | $40.60B | $36.70B |
Volume | 508,758 | 6,435,094 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $36.17 |
52-Week Low | $504.70 | $25.19 |
Typical Hold Time | 46 Days | 85 Days |
Enterprise Value | $41.50B | $19.33B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $511.65, up 1.02% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $4.3B in 2025 to $4.6B projected for 2026, with net income margins improving to 24.61%. Recent acquisitions like CoVetAI and product expansions in the UK highlight strategic growth initiatives. Technical indicators show resistance at $515 and support at $509, with moving averages signaling bearish pressure.
Outlook remains positive with a consensus price target of $665 (30% upside), supported by 13 buy ratings. Risks include premium valuation (P/E 35.96) and FX exposure. Earnings beats in recent quarters and raised 2026 EPS guidance reinforce growth trajectory, though insider selling and technical weakness warrant monitoring.
JD.com trades at $26.92, up 1.05% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.93 surpassing the $0.86 forecast. The stock appears fundamentally undervalued with a P/E of 17.91 and P/S of 0.2, while revenue for 2025 reached $1.31 trillion. Analyst sentiment is strongly positive, with a consensus price target of $35.86 and 32 buy ratings.
The outlook is mixed; deep valuation discounts and strong cash flow offer significant upside potential, but declining revenue growth, competitive pressures in Chinese e-commerce, and regulatory scrutiny pose risks. Investors should weigh the attractive valuation against macroeconomic headwinds and execution challenges in core retail segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
